A global medical device company is looking for traditional M&A opportunities in mature businesses as well as strategic equity investments in early stage companies via a corporate venture fund, primarily focused on Series A through D rounds. Initial investments usually range from $2M – $3M with some capital reserved for follow on investments and are generally flexible in terms of structure, with no special rights attached. Although these investments are strategic in nature, the fund does look for financial returns. The firm looks to deploy around $20 – $30M annually into these early stage ventures, and is open to companies on a global basis.
The firm has four main business segments in orthopedic reconstruction, advanced wound management, sports medicine and ENT. The firm is open to any technologies within these areas, from services to medical devices and is beginning to look at healthcare IT solutions that have utility in these segments. The firm will look at technologies as early as prototype phase and looks to leverage their internal expertise to evaluate their viability. The company has no restrictions in terms of regulatory pathway and will look at class I through class III products.
The firm has preference for experienced management teams but has no strict company or management requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 